Luminol-conjugated cyclodextrin biological nanoparticles for the treatment of severe burn-induced intestinal barrier disruption

Yajun Song; Yang Li; Wengang Hu; Feng Li; Hao Sheng; Chibing Huang; Xin Gou; Jingming Hou; Ji Zheng; Ya Xiao

doi:10.1093/burnst/tkad054

您当前的位置：

首页 >

文章列表页 >

Luminol-conjugated cyclodextrin biological nanoparticles for the treatment of severe burn-induced intestinal barrier disruption

更新时间：2024-04-19

- Luminol-conjugated cyclodextrin biological nanoparticles for the treatment of severe burn-induced intestinal barrier disruption
- Luminol-conjugated cyclodextrin biological nanoparticles for the treatment of severe burn-induced intestinal barrier disruption
- Burns & Trauma 2024年12卷第1期
- 作者机构：
  
  1. Department of Urology
  2. The Army Medical University
  3. Department of Urology, The First Affiliated Hospital of Chongqing Medical University
  4. Institute of Burn Research, Southwest Hospital
  5. Department of Urology, Chongqing University Three Gorges Hospital
  6. Department of Rehabilitation
- 作者简介：
- 基金信息：
  
  This work was supported by the General Project of Natural Science Foundation Project of Chongqing (No. cstc2021jcyj-msxmX0611), the Chongqing Doctor “Through Train” Scientific Research Project (CSTBBSXM2022-JCX0007), and the Education and Training Reform Project of the Army Medical University (CSTBBSXM2022-JCX0007).
- DOI：10.1093/burnst/tkad054
  中图分类号：
- 纸质出版日期：2024，
  
  网络出版日期：2024-3-13，
扫描看全文
Yajun Song, Yang Li, Wengang Hu, 等. Luminol-conjugated cyclodextrin biological nanoparticles for the treatment of severe burn-induced intestinal barrier disruption[J]. Burns & Trauma, 2024,12(1).

Yajun Song, Yang Li, Wengang Hu, Feng Li, Hao Sheng, Chibing Huang, Xin Gou, Jingming Hou, Ji Zheng, Ya Xiao, Luminol-conjugated cyclodextrin biological nanoparticles for the treatment of severe burn-induced intestinal barrier disruption, Burns & Trauma, Volume 12, 2024, tkad054, https://doi.org/10.1093/burnst/tkad054
Yajun Song, Yang Li, Wengang Hu, 等. Luminol-conjugated cyclodextrin biological nanoparticles for the treatment of severe burn-induced intestinal barrier disruption[J]. Burns & Trauma, 2024,12(1). DOI： 10.1093/burnst/tkad054.

Yajun Song, Yang Li, Wengang Hu, Feng Li, Hao Sheng, Chibing Huang, Xin Gou, Jingming Hou, Ji Zheng, Ya Xiao, Luminol-conjugated cyclodextrin biological nanoparticles for the treatment of severe burn-induced intestinal barrier disruption, Burns & Trauma, Volume 12, 2024, tkad054, https://doi.org/10.1093/burnst/tkad054 DOI：

摘要

Abstract

BackgroundThe breakdown of intestinal barrier integrity occurs after severe burn injury and is responsible for the subsequent reactions of inflammation and oxidative stress. A new protective strategy for the intestinal barrier is urgently needed due to the limitations of the traditional methods. Recently

the application of nanoparticles has become one of the promising therapies for many inflammation-related diseases or oxidative damage. Herein

we developed a new anti-inflammatory and antioxidant nanoparticle named luminol-conjugated cyclodextrin (LCD) and aimed to evaluate its protective effects in severe burn-induced intestinal injury.MethodsFirst

LCD nanoparticles

engineered with covalent conjugation between luminol and β-cyclodextrin (β-CD)

were synthesized and examined. Then a mouse burn model was successfully established before the mouse body weight

intestinal histopathological manifestation

permeability

tight junction (TJ) expression and pro-inflammatory cytokines were determined in different groups. The proliferation

apoptosis

migration and reactive oxygen species (ROS) of intestinal epithelial cells (IECs) were assessed. Intraepithelial lymphocytes (IELs) were isolated and cultured for analysis by flow cytometry.ResultsLCD nanoparticle treatment significantly relieved the symptoms of burn-induced intestinal injury in the mouse model

including body weight loss and intestinal permeability abnormalities. Moreover

LCD nanoparticles remarkably recovered the mechanical barrier of the intestine after severe burn

renewed TJ structures

promoted IEC proliferation and migration

and inhibited IEC apoptosis. Mechanistically

LCD nanoparticles dramatically alleviated pro-inflammation factors (tumor necrosis factor-α

IL-17A) and ROS accumulation

which could be highly involved in intestinal barrier disruption. Furthermore

an increase in IL-17A and the proportion of IL-17A+Vγ4+ γδ T subtype cells was also observed in vitro in LPS-treated Vγ4+ γδ T cells

but the use of LCD nanoparticles suppressed this increase.ConclusionsTaken together

these findings demonstrate that LCD nanoparticles have the protective ability to ameliorate intestinal barrier disruption and provide a therapeutic intervention for burn-induced intestinal injury.

关键词

Keywords

LCD nanoparticleBurnIntestinal barrierInflammatory cytokinesReactive oxygen speciesVγ4+ γδ T cellsLuminol-conjugated cyclodextrin

references

1.Jeschke MG, van Baar ME, Choudhry MA, Chung KK, Gibran NS, Logsetty S, et al. Burn injury. Nat Rev Dis Primers. 2020;6:11. https://doi.org/10.1038/s41572-020-0145-5.

2.Wang H, Liu Y, Cai K, Zhang B, Tang S, Zhang W, et al. Antibacterial polysaccharide-based hydrogel dressing containing plant essential oil for burn wound healing. Burns. Trauma. 2021;9:1–14. https://doi.org/10.1093/burnst/tkab041.

3.Shen ZA. Preliminary discussion on the prevention and treatment of shock after severe burns. Zhonghua zheng xing shao shang wai ke za zhi. 2022;38:9–12. https://doi.org/10.3760/cma.j.cn501120-20211130-00402.

4.Wang Y, Beekman J, Hew J, Jackson S, Issler-Fisher AC, Parungao R, et al. Burn injury: challenges and advances in burn wound healing, infection, pain and scarring. Adv Drug Deliv Rev. 2018;123:3–17. https://doi.org/10.1016/j.addr.2017.09.018.

5.Qin C, Jiang Y, Chen X, Bian Y, Wang Y, Xie K, et al. Dexmedetomidine protects against burn-induced intestinal barrier injury via the MLCK/p-MLC signalling pathway. Burns. 2021;47:1576–85. https://doi.org/10.1016/j.burns.2021.01.017.

6.Blander JM. Death in the intestinal epithelium-basic biology and implications for inflammatory bowel disease. FEBS J. 2016;283:2720–30. https://doi.org/10.1111/febs.13771.

7.Meng M, Klingensmith NJ, Coopersmith CM. New insights into the gut as the driver of critical illness and organ failure. Curr Opin Crit Care. 2017;23:143–8. https://doi.org/10.1097/MCC.0000000000000386.

8.Wang C, Li Q, Ren J. Microbiota-immune interaction in the pathogenesis of gut-derived infection. Front Immunol. 2019;10:1873. https://doi.org/10.3389/fimmu.2019.01873.

9.Li Y, Huang Z, Yan R, Liu M, Bai Y, Liang G, et al. Vγ4 γδ T cells provide an early source of IL-17A and accelerate skin graft rejection. J Invest Dermatol. 2017;137:2513–22. https://doi.org/10.1016/j.jid.2017.03.043.

10.Cai Y, Shen X, Ding C, Qi C, Li K, Li X, et al. Pivotal role of dermal IL-17-producing γδ T cells in skin inflammation. Immunity. 2011;35:596–610. https://doi.org/10.1016/j.immuni.2011.08.001.

11.Eyerich K, Dimartino V, Cavani A. IL-17 and IL-22 in immunity: driving protection and pathology. Eur J Immunol. 2017;47:607–14. https://doi.org/10.1002/eji.201646723.

12.Halwani R, Sultana A, Vazquez-Tello A, Jamhawi A, Al-Masri AA, Al-Muhsen S. Th-17 regulatory cytokines IL-21, IL-23, and IL-6 enhance neutrophil production of IL-17 cytokines during asthma. J Asthma. 2017;54:893–904. https://doi.org/10.1080/02770903.2017.1283696.

13.Meng Q, Liu J, Lin F, Bao L, Jiang Y, Zheng L, et al. IL-17 contributes to the pathogenesis of obliterative bronchiolitis via regulation of M1 macrophages polarization in murine heterotopic trachea transplantation models. Int Immunopharmacol. 2017;52:51–60. https://doi.org/10.1016/j.intimp.2017.08.022.

14.Moschen AR, Tilg H, Raine T. IL-12, IL-23 and IL-17 in IBD: immunobiology and therapeutic targeting. Nat Rev Gastroenterol Hepatol. 2019;16:185–96. https://doi.org/10.1038/s41575-018-0084-8.

15.Song Y, Li Y, Xiao Y, Hu W, Wang X, Wang P, et al. Neutralization of interleukin-17A alleviates burn-induced intestinal barrier disruption via reducing pro-inflammatory cytokines in a mouse model. Burns Trauma. 2019;7:37. https://doi.org/10.1186/s41038-019-0177-9.

16.Honvo G, Leclercq V, Geerinck A, Thomas T, Veronese N, Charles A, et al. Safety of topical non-steroidal anti-inflammatory drugs in osteoarthritis: outcomes of a systematic review and meta-analysis. Drugs Aging. 2019;36:45–64. https://doi.org/10.1007/s40266-019-00661-0.

17.Wichmann MA, Cruickshanks KJ, Carlsson CM, Chappell R, Fischer ME, Klein BE, et al. NSAID use and incident cognitive impairment in a population-based cohort. Alzheimer Dis Assoc Disord. 2016;30:105–12.

18.Nanau RM, Neuman MG. Ibuprofen-induced hypersensitivity syndrome. Transl Res. 2010;155:275–93. https://doi.org/10.1016/j.trsl.2010.01.005.

19.MacRitchie N, Di Francesco V, Ferreira MFMM, Guzik TJ, Decuzzi P, Maffia P. Nanoparticle theranostics in cardiovascular inflammation. Semin Immunol. 2021;56:1–10. https://doi.org/10.1016/j.smim.2021.101536.

20.Weaver JB, Ness DB, Fields J, Jyoti D, Gordon-Wylie SW, Berwin BL, et al. Identifying in vivo inflammation using magnetic nanoparticle spectra. Phys Med Biol. 2020;65:1–9. https://doi.org/10.1088/1361-6560/ab8afd.

21.Kwon SP, Hwang BH, Park EH, Kim HY, Lee JR, Kang M, et al. Nanoparticle-mediated blocking of excessive inflammation for prevention of heart failure following myocardial infarction. Small. 2021;17:1–12. https://doi.org/10.1002/smll.202101207.

22.Yuan J, Li L, Yang Q, Ran H, Wang J, Hu K, et al. Targeted treatment of ischemic wtroke by bioactive nanoparticle-derived reactive oxygen species responsive and inflammation-resolving nanotherapies. ACS Nano. 2021;15:16076–94. https://doi.org/10.1021/acsnano.1c04753.

23.Wang Y, Li L, Zhao W, Dou Y, An H, Tao H, et al. Targeted therapy of atherosclerosis by a broad-spectrum reactive oxygen species scavenging nanoparticle with intrinsic anti-inflammatory activity. ACS Nano. 2018;12:8943–60. https://doi.org/10.1021/acsnano.8b02037.

24.Zimmer S, Grebe A, Bakke SS, Bode N, Halvorsen B, Ulas T, et al. Cyclodextrin promotes atherosclerosis regression via macrophage reprogramming. Sci Transl Med. 2016;8:333ra50. https://doi.org/10.1126/scitranslmed.aad6100.

25.Guo J, Li D, Tao H, Li G, Liu R, Dou Y, et al. Cyclodextrin-derived intrinsically bioactive nanoparticles for treatment of acute and chronic inflammatory diseases. Adv Mater. 2019;31:1–8. https://doi.org/10.1002/adma.201904607.

26.Matassoli FL, Leao IC, Bezerra BB, Pollard RB, Lütjohann D, Hildreth JEK, et al. Hydroxypropyl-beta-cyclodextrin reduces inflammatory signaling from monocytes: possible implications for suppression of HIV chronic immune activation. mSphere. 2018;3:e00497–18. https://doi.org/10.1128/mSphere.00497-18.

27.Tian B, Hua S, Liu J. Cyclodextrin-based delivery systems for chemotherapeutic anticancer drugs: a review. Carbohydr Polym. 2020;232:1–52. https://doi.org/10.1016/j.carbpol.2019.115805.

28.Song Y, Hu W, Xiao Y, Li Y, Wang X, He W, et al. Keratinocyte growth factor ameliorates mycophenolate mofetil-induced intestinal barrier disruption in mice. Mol Immunol. 2020;124:61–9. https://doi.org/10.1016/j.molimm.2020.04.012.

29.Ciesielska A, Matyjek M, Kwiatkowska K. TLR4 and CD14 trafficking and its influence on LPS-induced pro-inflammatory signaling. Cell Mol Life Sci. 2021;78:1233–61. https://doi.org/10.1007/s00018-020-03656-y.

30.Sul OJ, Ra SW. Quercetin prevents LPS-induced oxidative stress and inflammation by modulating NOX2/ROS/NF-kB in lung epithelial cells. Molecules. 2021;26:6949. https://doi.org/10.3390/molecules26226949.

31.Liu M, Xie W, Wan X, Deng T. Clostridium butyricum protects intestinal barrier function via upregulation of tight junction proteins and activation of the Akt/mTOR signaling pathway in a mouse model of dextran sodium sulfate-induced colitis. Exp Ther Med. 2020;20:10. https://doi.org/10.3892/etm.2020.9138.

32.Bindu S, Mazumder S, Bandyopadhyay U. Non-steroidal anti-inflammatory drugs (NSAIDs) and organ damage: a current perspective. Biochem Pharmacol. 2020;180:1–21. https://doi.org/10.1016/j.bcp.2020.114147.

33.Szeto CC, Sugano K, Wang JG, Fujimoto K, Whittle S, Modi GK, et al. Non- steroidal anti-inflammatory drug (NSAID) therapy in patients with hypertension, cardiovascular, renal or gastrointestinal comorbidities: joint APAGE/APLAR/APSDE/APSH/ APSN/PoA recommendations. Gut. 2020;69:617–29. https://doi.org/10.1136/gutjnl-2019-319300.

34.Zeng M, Shao A, Li H, Tang Y, Li Q, Guo Z, et al. Peptide receptor-targeted fuorescent probe: visualization and discrimination between chronic and acute ulcerative colitis. ACS Appl Mater Interfaces. 2017;9:13029–36. https://doi.org/10.1021/acsami.7b00936.

35.Lee Y, Sugihara K, Gillilland MG, Jon S, Kamada N, Moon JJ. Hyaluronic acid-bilirubin nanomedicine for targeted modulation of dysregulated intestinal barrier, microbiome and immune responses in colitis. Nat Mater. 2020;19:118–26. https://doi.org/10.1038/s41563-019-0462-9.

36.Huang Y, Wang Y, Feng Y, Wang P, He X, Ren H, et al. Role of endoplasmic reticulum stress-autophagy Axis in severe burn-induced intestinal tight junction barrier dysfunction in mice. Front Physiol. 2019;10:606. https://doi.org/10.3389/fphys.2019.00606.

37.Marchiando AM, Graham WV, Turner JR. Epithelial barriers in homeostasis and disease. Annu Rev Pathol-Mech. 2010;5:119–44. https://doi.org/10.1146/annurev.pathol.4.110807.092135.

38.He W, Wang Y, Wang P, Wang F. Intestinal barrier dysfunction in severe burn injury. Burns Trauma. 2019;7:24. https://doi.org/10.1186/s41038-019-0162-3.

39.Shen L, Weber CR, Raleigh DR, Yu D, Turner JR. Tight junction pore and leak pathways: a dynamic duo. Annu Rev Physiol. 2011;73:283–309. https://doi.org/10.1146/annurev-physiol-012110-142150.

40.Chen C, Wang P, Su Q, Wang S, Wang F. Myosin light chain kinase mediates intestinal barrier disruption following burn injury. PLoS One. 2012;7:1–7. https://doi.org/10.1371/journal.pone.0034946.

41.Huang Y, Feng Y, Wang Y, Wang P, Wang F, Ren H. Severe burn-induced intestinal epithelial barrier dysfunction is associated with endoplasmic reticulum stress and autophagy in mice. Front Physiol. 2018;9:441. https://doi.org/10.3389/fphys.2018.00441.

42.Zhuang Y, Wu H, Wang X, He J, He S, Yin Y. Resveratrol attenuates oxidative stress-induced intestinal barrier injury through PI3K/Akt-mediated Nrf2 signaling pathway. Oxidative Med Cell Longev. 2019;2019:7591840. https://doi.org/10.1155/2019/7591840.

43.Zhang W, Dai XL, Jin X, Huang MC, Shan J, Chen XL, et al. Promotion of wound healing by a thermosensitive and sprayable hydrogel. Smart Mater Med. 2023;4:134–45. https://doi.org/10.1016/j.smaim.2022.08.004.

44.Jin X, Zhang W, Shan J, He J, Qian H, Chen X, et al. Thermosensitive hydrogel loaded with nickel-copper bimetallic hollow Nanospheres with SOD and CAT enzymatic-like activity promotes acute wound healing. ACS Appl Mater Interfaces. 2022;14:50677–91. https://doi.org/10.1021/acsami.2c17242.

45.Gong ZY, Yuan ZQ, Dong ZW, Peng YZ. Glutamine with probiotics attenuates intestinal inflammation and oxidative stress in a rat burn injury model through altered iNOS gene aberrant methylation. Am J Transl Res. 2017;9:2535–47.

46.El Ayadi A, Salsbury JR, Enkhbaatar P, Herndon DN, Ansari NH. Metal chelation attenuates oxidative stress, inflammation, and vertical burn progression in a porcine brass comb burn model. Redox Biol. 2021;45:1–12. https://doi.org/10.1016/j.redox.2021.102034.

47.Wan Y, Fu Y, Wang F, Sinclair AJ, Li D. Protective effects of a lipid extract from hard-shelled mussel (mytilus coruscus) on intestinal integrity after lipopolysaccharide challenge in mice. Nutrients. 2018;10:860. https://doi.org/10.3390/nu10070860.

48.Shi Y, Wang ZE, Wu W, Wu D, Wang C, Peng X. Glutamine protects intestinal mucosa and promotes its transport after burn injury in rats. Int J Clin Exp Pathol. 2018;11:1825–35.

49.Adiliaghdam F, Cavallaro P, Mohad V, Almpani M, Kühn F, Gharedaghi MH, et al. Targeting the gut to prevent sepsis from a cutaneous burn. JCI Insight. 2020;5:e137128. https://doi.org/10.1172/jci.insight.137128.

50.Benakis C, Brea D, Caballero S, Faraco G, Moore J, Murphy M, et al. Commensal microbiota affects ischemic stroke outcome by regulating intestinal γδ T cells. Nat Med. 2016;22:516–23. https://doi.org/10.1038/nm.4068.

51.Wang DD, Zhao YF, Wang GY, Sun B, Kong QF, Zhao K, et al. IL-17 potentiates neuronal injury induced by oxygen-glucose deprivation and affects neuronal IL-17 receptor expression. J Neuroimmunol. 2009;212:17–25. https://doi.org/10.1016/j.jneuroim.2009.04.007.

52.Gelderblom M, Weymar A, Bernreuther C, Velden J, Arunachalam P, Steinbach K, et al. Neutralization of the IL-17 axis diminishes neutrophil invasion and protects from ischemic stroke. Blood. 2012;120:3793–802. https://doi.org/10.1182/blood-2012-02-412726.

53.Konoeda F, Shichita T, Yoshida H, Sugiyama Y, Muto G, Hasegawa E, et al. Therapeutic effect of IL-12/23 and their signaling pathway blockade on brain ischemia model. Biochem Biophys Res Commun. 2010;402:500–6. https://doi.org/10.1016/j.bbrc.2010.10.058.

54.Lu L, Wang Y, Zhou L, Li Y, Zhang X, Hu X, et al. Vγ4 T cell derived IL-17A is essential for amplification of inflammatory cascades in ischemic brain tissue after stroke. Int Immunopharmacol. 2021;96:107678. https://doi.org/10.1016/j.intimp.2021.107678.

55.Prinz I, Silva-Santos B, Pennington DJ. Functional development of γδ T cells. Eur J Immunol. 2013;43:1988–94. https://doi.org/10.1002/eji.201343759.

56.Sumaria N, Grandjean CL, Silva-Santos B, Pennington DJ. Strong TCRγδ signaling prohibits thymic development of IL-17A-secreting γδ T cells. Cell Rep. 2017;19:2469–76. https://doi.org/10.1016/j.celrep.2017.05.071.

57.Blink SE, Caldis MW, Goings GE, Harp CT, Malissen B, Prinz I, et al. γδ T cell subsets play opposing roles in regulating experimental autoimmune encephalomyelitis. Cell Immunol. 2014;290:39–51. https://doi.org/10.1016/j.cellimm.2014.04.013.

58.Li Y, Wu J, Luo G, He W. Functions of Vγ4 T cells and dendritic epidermal T cells on skin wound healing. Front Immunol. 2018;9:1099. https://doi.org/10.3389/fimmu.2018.01099.

59.O'Brien RL, Born WK. Two functionally distinct subsets of IL-17 producing γδ T cells. Immunol Rev. 2020;298:10–24. https://doi.org/10.1111/imr.12905.

60.Cong LH, Li T, Wang H, Wu YN, Wang SP, Zhao YY, et al. IL-17A-producing T cells exacerbate fine particulate matter-induced lung inflammation and fibrosis by inhibiting PI3K/Akt/mTOR-mediated autophagy. J Cell Mol Med. 2020;24:8532–44. https://doi.org/10.1111/jcmm.15475.

61.Chen G, Zhou Y, Zhang W, Qin Y, Wei B, Sun Y, et al. Methyl-β-cyclodextrin suppresses the monocyte-endothelial adhesion triggered by lipopolysaccharide (LPS) or oxidized low-density lipoprotein (oxLDL). Pharm Biol. 2021;59:1036–44.

62.Lin T, Ding Z, Li N, Xu J, Luo G, Liu J, et al. Seleno-cyclodextrin sensitises human breast cancer cells to TRAIL-induced apoptosis through DR5 induction and NF-κB suppression. Eur J Cancer. 2011;47:1890–907. https://doi.org/10.1016/j.ejca.2011.04.004.

63.Wang L, Zhen H, Yao W, Bian F, Zhou F, Mao X, et al. Lipid raft-dependent activation of dual oxidase 1/H2O2/NF-κB pathway in bronchial epithelial cells. Am J Physiol Cell Physiol. 2011;301:C171–80. https://doi.org/10.1152/ajpcell.00363.2010.

查看原文

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

The Notch pathway attenuates burn-induced acute lung injury in rats by repressing reactive oxygen species

Broadening horizons: ferroptosis as a new target for traumatic brain injury

The impact of burn injury on the central nervous system

The impact of COVID-19 on clinical outcomes of burn patients

In vitro comparison of human plasma-based and self-assembled tissue-engineered skin substitutes: two different manufacturing processes for the treatment of deep and difficult to heal injuries